Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial

Introduction We have recently described an increased lymphocytic infiltration rate in breast carcinoma tissue is a significant response predictor for anthracycline/taxane-based neoadjuvant chemotherapy (NACT). The aim of this study was to prospectively validate the tumor-associated lymphocyte infiltrate as predictive marker for response to anthracycline/taxane-based NACT. Patients and Methods The immunological infiltrate was prospectively evaluated in a total of 313 core biopsies from HER2 negative patients of the multicenter PREDICT study, a substudy of the neoadjuvant GeparQuinto study. Intratumoral lymphocytes (iTuLy), stromal lymphocytes (strLy) as well as lymphocyte-predominant breast cancer (LPBC) were evaluated by histopathological assessment. Pathological complete response (pCR) rates were analyzed and compared between the defined subgroups using the exact test of Fisher. Results Patients with lymphocyte-predominant breast cancer (LPBC) had a significantly increased pCR rate of 36.6%, compared to non-LPBC patients (14.3%, p<0.001). LPBC and stromal lymphocytes were significantly independent predictors for pCR in multivariate analysis (LPBC: OR 2.7, p = 0.003, strLy: OR 1.2, p = 0.01). The amount of intratumoral lymphocytes was significantly predictive for pCR in univariate (OR 1.2, p = 0.01) but not in multivariate logistic regression analysis (OR 1.2, p = 0.11). Conclusion Confirming previous investigations of our group, we have prospectively validated in an independent cohort that an increased immunological infiltrate in breast tumor tissue is predictive for response to anthracycline/taxane-based NACT. Patients with LPBC and increased stromal lymphocyte infiltration have significantly increased pCR rates. The lymphocytic infiltrate is a promising additional parameter for histopathological evaluation of breast cancer core biopsies.

[1]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  L. Coussens,et al.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.

[3]  A. Houghton,et al.  Immune recognition of self in immunity against cancer. , 2004, The Journal of clinical investigation.

[4]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[8]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[9]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[10]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[11]  H. Ditzel,et al.  Translocation of an Intracellular Antigen to the Surface of Medullary Breast Cancer Cells Early in Apoptosis Allows for an Antigen-Driven Antibody Response Elicited by Tumor-Infiltrating B Cells1 , 2002, The Journal of Immunology.

[12]  H. Kölbl,et al.  The humoral immune system has a key prognostic impact in node-negative breast cancer. , 2008, Cancer research.

[13]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[14]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[16]  G. Nicolardi,et al.  Computerised counting of tumour infiltrating lymphocytes in 90 breast cancer specimens. , 1999, Cancer letters.

[17]  B. Chauffert,et al.  Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.

[18]  I. Ellis,et al.  The prognostic significance of B lymphocytes in invasive carcinoma of the breast , 2012, Breast Cancer Research and Treatment.

[19]  H. Ditzel,et al.  The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[21]  V. Kosma,et al.  Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.

[22]  B. Melichar,et al.  Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma , 2008, Cancer investigation.

[23]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Laurence Zitvogel,et al.  Immune parameters affecting the efficacy of chemotherapeutic regimens , 2011, Nature Reviews Clinical Oncology.

[25]  E. Hersh,et al.  Naturally occurring B-cell responses to breast cancer , 2003, Cancer Immunology, Immunotherapy.

[26]  Timothy R. Crespin,et al.  Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment , 2004, Clinical Cancer Research.

[27]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[29]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Disis.  Immune regulation of cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[32]  C. Punt,et al.  Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes , 1994, Cancer Immunology, Immunotherapy.

[33]  P. Telleman,et al.  Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. , 2001, Cancer research.

[34]  I. Fentiman,et al.  Inflammation and breast cancer , 2013 .

[35]  Daniel Rodríguez‐Pinto.  B cells as antigen presenting cells. , 2005, Cellular immunology.

[36]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Oshikiri,et al.  Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma , 2006, British Journal of Cancer.

[39]  C. Ichim,et al.  Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy , 2005, Journal of Translational Medicine.

[40]  F. Ghiringhelli,et al.  Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity , 2008, Cancer Immunology, Immunotherapy.

[41]  T. Shibata,et al.  Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer , 2012, Breast Cancer Research and Treatment.

[42]  L. Zitvogel,et al.  Immune response against dying tumor cells. , 2004, Advances in immunology.

[43]  B. Nelson,et al.  CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes , 2010, The Journal of Immunology.

[44]  M. Smyth,et al.  Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth , 2009, PloS one.

[45]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[46]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[47]  William J. Gradishar,et al.  Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer , 2004, Clinical Cancer Research.

[48]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[49]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[50]  I. Ellis,et al.  An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer , 2011, Breast Cancer Research and Treatment.

[51]  S. Ménard,et al.  FOXP3 expression and overall survival in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Ménard,et al.  Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.